Cancer Letters
Volume 227, Issue 1 , Pages 9-23, 8 September 2005

Antitumor activity of HER-2 inhibitors

Wyeth Research, 401 N. Middletown Road, Pearl River, NY 10965, USA

Received 2 November 2004; accepted 7 November 2004.

Abstract 

Activation of intracellular mitogenic signal transduction pathways driven by the ErbB family of receptor tyrosine kinases has been implicated in a variety of cancers. Amongst these, the tumorigenic roles of the Epidermal Growth Factor receptor (EGFR) and HER-2 have been most extensively studied. Therapeutic antibodies and small molecule kinase inhibitors targeting EGFR have recently received regulatory agency approval for the treatment of colon and lung cancer, respectively. In this review, I briefly describe these agents and their potential use in inhibiting the growth of tumors that overexpress HER-2. I also discuss other therapeutics currently available or being developed specifically to target HER-2 dependent tumors.

Keywords: HER-2, ErbB-2, neu, Receptor tyrosine kinase, Kinase inhibitors, Breast cancer

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0304-3835(04)00874-2

doi:10.1016/j.canlet.2004.11.015

Cancer Letters
Volume 227, Issue 1 , Pages 9-23, 8 September 2005

Article Tools